Trials in Africa of a new malaria vaccine have shown it more than halves the number of serious bouts of the disease in small children, it was revealed yesterday.Expectations are high for the vaccine, which has already shown promise in early trials. The latest trial results, published online in the New England Journal of Medicine (NEJM), are better than before. Early trials in Mozambique found the vaccine reduced by almost a third the number of cases of malaria warranting clinical care. In the new trials in Tanzania and Kenya, it reduced such cases by 53% in five- to 17-month-old babies. Malaria kills almost a million people a year, mostly babies and small children in Africa.This is the latest of a series of trials designed to test the efficacy of the vaccine RTS,S - which is being developed by GlaxoSmithKline Biologicals. The improved efficacy in Kenya and Tanzania resulted from using...
- Promising trials of malaria vaccine lead to calls for Phase 3 developmentMon, 8 Dec 2008, 12:32:14 EST
- Malaria vaccine candidate, RTS,S reduces the risk of malaria by half in African childrenTue, 18 Oct 2011, 14:34:48 EDT
- UM School of Medicine scientists find new malaria vaccine is safe and protective in childrenWed, 3 Feb 2010, 20:54:00 EST
- Adaptive trial designs could accelerate HIV vaccine developmentWed, 20 Apr 2011, 14:36:03 EDT
- Weakened malaria parasites form basis of new vaccine strategyThu, 8 Sep 2011, 16:37:55 EDT